Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: June 6, 2002
Last updated: July 17, 2013
Last verified: March 2003
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2008
  Primary Completion Date: May 2003 (Final data collection date for primary outcome measure)